Seminars in Arthritis and Rheumatism
Volume 39, Issue 4 , Pages 269-277 , February 2010

Determinants of Morbidity and Mortality of Systemic Sclerosis in Canada

  • Firas F. Al-Dhaher, BSc (Hons), MD

      Affiliations

    • The University of Western Ontario, London, Ontario, Canada
    • ,
  • Janet E. Pope, MD, MPH, FRCPC

      Affiliations

    • Professor of Medicine and Epidemiology and Biostatistics, Division of Rheumatology, Department of Medicine, The University of Western Ontario, London, Ontario, Canada
    • Corresponding Author InformationAddress reprint requests to Janet E. Pope, MD, MPH, FRCPC, St. Joseph's Health Care London, 268 Grosvenor Street, London, ON, N6A 4V2, Canada
    • ,
  • Janine M. Ouimet, BSc (Hons), MSc

      Affiliations

    • Epidemiology & Biostatistics, The University of Western Ontario, London, Ontario, Canada

References 

  1. Seibold J. Connective tissue diseases characterized by fibrosis. In:  Ruddy S,  Harris ED,  Sledge CB editor. Textbook of Rheumatology. Vol. 2. Philadelphia: WB Saunders Co; 2001;p. 1133–1159
  2. Wigley F. Systemic sclerosis. B. Clinical features. In:  Klippel JH editors. Primer on the Rheumatic Diseases. Atlanta: The Arthritis Foundation; 2001;p. 357–364
  3. Steen V. Epidemiology of systemic sclerosis. In:  Hochberg MC,  Silman AJ,  Smolen JS,  Weinblatt ME,  Weisman MH editor. Rheumatology. Vol. 2. Toronto: Elsevier Limited (Mosby); 2003;p. 1455–1461
  4. Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect. 1999;107(Suppl 5):743–748
  5. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81(2):139–153
  6. Silman AJ. Scleroderma—demographics and survival. J Rheumatol. 1997;24(Suppl 48):58–61
  7. Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246–2255
  8. Abu-Shakra M, Lee P. Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol. 1995;22(11):2100–2102
  9. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003;29(2):239–254
  10. Altman RD, Medsger TA, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 1991;34(4):403–413
  11. Medsger TA, Masi AT. Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med. 1971;74(5):714–721
  12. Steen V, Costantino J, Shapiro A, Medsger TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113(5):352–357
  13. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore). 2002;81(2):154–167
  14. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol. 1988;15(2):276–283
  15. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am. 2003;29(2):315–333
  16. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11):2437–2444
  17. Harrison BJ, Silman AJ, Hider SL, Herrick AL. Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum. 2002;46(12):3312–3316
  18. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 1994;37(1):75–83
  19. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980 May;23(5):581–590
  20. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–205
  21. Ferri C, Bernini L, Cecchetti R, Latorraca A, Marotta G, Pasero G, et al. Cutaneous and serologic subsets of systemic sclerosis. J Rheumatol. 1991;18(12):1826–1832
  22. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, et al. Mortality in systemic sclerosis (scleroderma). Q J Med. 1992;82(298):139–148
  23. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940–944Epub 2007 Feb 28
  24. Bennett R, Bluestone R, Holt PJ, Bywaters EG. Survival in scleroderma. Ann Rheum Dis. 1971;30(6):581–588
  25. Rowell NR. The prognosis of systemic sclerosis. Br J Dermatol. 1976;95(1):57–60
  26. Eason RJ, Tan PL, Gow PJ. Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features. Aust NZ J Med. 1981;11(6):657–662
  27. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986;13(5):911–916
  28. Simeon CP, Armadans L, Fonollosa V, Vilardell M, Candell J, Tolosa C, et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis. 1997;56(12):723–728
  29. Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol. 1996;35(11):1122–1126
  30. Nishioka K, Katayama I, Kondo H, Shinkai H, Ueki H, Tamaki K, et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc) (Scleroderma Research Committee Japan). J Dermatol. 1996;23(10):677–682
  31. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis. 1998;57(11):682–686
  32. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol. 1998;37(7):750–755
  33. Nagy Z, Czirjak L. Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol. 1997;16(5):454–460
  34. Tuffanelli DL, Winkelmann RK. Systemic scleroderma (A clinical study of 727 cases). Arch Dermatol. 1961;84:359–371
  35. Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan RH, Burns CJ, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum. 1997;40(4):734–742
  36. Kuwana M, Sato S, Kikuchi K, Kawaguchi Y, Fujisaku A, Misaki Y, et al. Evaluation of functional disability using the health assessment questionnaire in Japanese patients with systemic sclerosis. J Rheumatol. 2003;30(6):1253–1258
  37. Nietert PJ, Silver RM, Mitchell HC, Shaftman SR, Tilley BC. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol. 2005;32(10):1888–1892
  38. Ruangjutipopan S, Kasitanon N, Louthrenoo W, Sukitawut W, Wichainun R. Causes of death and poor survival prognostic factors in thai patients with systemic sclerosis. J Med Assoc Thai. 2002;85(11):1204–1209
  39. Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford). 2003;42(1):71–75
  40. Wynn J, Fineberg N, Matzer L, Cortada X, Armstrong W, Dillion JC. Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J. 1985;110(1 Pt. 1):123–127
  41. Walker JG, Ahern MJ, Smith MD, Coleman M, Pile K, Rischmueller M. Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J. 2003;33(5-6):216–220
  42. Steen VD, Medsger TA. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000;133(8):600–603
  43. Gunduz OH, Fertig N, Lucas M, Medsger TA. Systemic sclerosis with renal crisis and pulmonary hypertension: a report of eleven cases. Arthritis Rheum. 2001;44(7):1663–1666
  44. Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis. 2003;62(2):146–150
  45. Medsger TA, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma) (A life-table analysis of clinical and demographic factors in 309 patients). Ann Intern Med. 1971;75(3):369–376
  46. Alamanos Y, Tsifetaki N, Voulgari PV, Siozos C, Tsamandouraki K, Alexiou GA, et al. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum. 2005;34(5):714–720
  47. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005;118(1):2–10
  48. Roberts-Thomson PJ, Walker JG, Lu TY, Esterman A, Hakendorf P, Smith MD. Scleroderma in South Australia: further epidemiological observations supporting a stochastic explanation. Intern Med J. 2006;36(8):489–497

 This research was funded in part by the University of Western Ontario Summer Research Training Program (SRTP) grant.

PII: S0049-0172(08)00116-9

doi: 10.1016/j.semarthrit.2008.06.002

Seminars in Arthritis and Rheumatism
Volume 39, Issue 4 , Pages 269-277 , February 2010

Article Tools